心脏保护疗效的比较:NOACs与Nattokinase-Bridging基础研究与临床发现的比较
Maja Muric1,2, Marina Nikolic1,2, Andreja Todorovic3
1Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Biomolecules
|August 29, 2024
概括
非维生素K对手口服抗凝剂 (NOACs) 和纳托金酶 (NK) 除了抗凝作用之外,还具有明显的心血管益处. 本综述比较了它们在现代心血管护理中的有效性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 非维生素K对抗剂口服抗凝剂 (NOACs) 在治疗心血管疾病方面比维生素K对抗剂 (VKAs) 有显著的进步.
- NOACs提供了诸如固定剂量和减少药物相互作用等优势,改善了治疗的坚持和安全性.
- 纳托金酶 (NK) 是一种来自食物的天然酶,表现出纤维溶解,抗高血压和抗动脉样硬化性质,表明更广泛的心脏保护潜力.
研究的目的:
- 介绍NOAC和NK的心脏保护性质,重点关注除了抗凝作用之外的作用.
- 通过叙述性综述阐明NOAC和NK的心脏保护疗效的比较.
- 突出NOAC和NK在当代心血管疾病管理中的各自作用.
主要方法:
- 叙述性综述综合了基础研究和临床发现的证据.
- 对心血管保护的NOACs和纳托金酶 (NK) 的比较分析.
- 对报告NOACs和NK的药理和生理影响的研究的评估.
主要成果:
- 在预防和治疗血栓栓塞事件方面,NOACs在临床上比VKAs更优越.
- 纳托金酶 (NK) 具有显著的纤维解酶活性和额外的心脏保护作用,包括血压调节和抗动脉样硬化.
- 在心血管保健中,NOAC和NK都是有前途的,具有不同的机制和应用.
结论:
- NOACs和NK提供了有价值的,尽管不同,心脏保护的好处,超出了他们的抗凝血剂或纤维溶解作用.
- 了解这些干预措施的比较疗效对于优化心血管医学患者的治疗结果至关重要.
- 进一步的研究可能会阐明NOAC和NK在综合性心血管疾病管理中的协同作用或互补作用.
相关概念视频
01:16Antianginal Drugs: Nitrates and β-Blockers
547
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
547
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K